2022 ADRC Data Core Workshop

# Estimate the time-to-conversion for Alzheimer's Disease using neuroimaging-genomics multi-modal deep survival analysis

Da Ma

Assistant Professor

Gerontology and Geriatric Medicine Alzheimer's Disease Research Center Center for Biomedical Informatics Wake Forest University School of Medicine

National Alzheimer's Coordinating Center



# Outlines

- Background / Aims
  - Predict time-to-conversion for dementia
  - Study the influence of different data modality on dementia conversion
- Study Design
  - Outcome measurement
  - Cohort Stratification
  - Independent variables
- Data processing / Feature extraction
  - Multi-type feature selection
  - Feature importance analysis Permutation test
- Experimental setup
  - Deep Survival Model design
  - Evaluation
- Results
- Conclusion

# **Study Aims**

- Predict time-to-conversion for Dementia of Alzheimer's Type (DAT)
  - Using multi-modal predictor, including: MRI, Genetics, Cerebrospinal Fluid (CSF) biomarker, Cognitive tests
- Study the influence of each data modality on disease prediction





#### **Study Design – Outcome Measurement**

# Predicting time-to-conversion - Survival analysis

- Probability of dementia risk
  - as a <u>function of time</u>
- Example:
  - APOE allele dementia risk



#### **Study Design – Outcome Measurements**

# Survival analysis - Sensoring

#### Survival Analysis:

 Analysis of the time an individual will experience an event of interest

#### **Event of Interest**

• Dementia onset (DAT diagnosis confirmation)

#### Left sensor

• Event happens before the first clinical visit (baseline)

#### **Right Sensor**

• Event happens after last clinical visit (final timepoint)



#### **Study Design – Outcome Measurements**

# Predicting time-to-conversion - Survival analysis

#### **Ground truth labels**

- 1. Event indicator:
  - 0 = Non-progressive (right sensored)
  - 1 = Progressive
- 2. Duration:
  - **Non-progressive**: Duration between the first and last visit
  - **Progressive**: Duration between first visit and DAT diagnosis confirmation



#### **Data - Study Participants**

• Training/evaluation cohort: ADNI-1

Subject grouping

Stratified Train/Valid/Test split

	Group name	Clinical progression	n
	sNC: stable NC	$NC \rightarrow NC$	109
Non- progressive	uNC: unstable NC	$NC \rightarrow MCI$	22
	sMCI: stable MCI	$MCI \rightarrow MCI$	101
	pNC: progressive NC	$NC \to MCI \to DAT$	14
Progressive	pMCI: progressive MCI	$MCI \rightarrow DAT$	155

Groups	Training set	Validation set	Testing set	Total
sNC	70	17	22	109
uNC	14	4	4	22
pNC	9	2	3	14
sMCI	65	16	20	101
pMCI	99	25	31	155
Total	257	64	80	401

Only baseline data were used for training

#### **Neuroimage & Genomic Feature Selection (Within Training Data)**



#### **Data – Input Features**

#### **Data modalities**

- MRI: 21 ROI volume (Z-standardized) (21 features)
- Genetic: 18 SNPs + 3 APOE alleles (21 features)
- DTC: 21 features
  - <u>Demographic</u> (4 features)
  - Cognitive <u>T</u>ests (11 features)
  - <u>C</u>SF (7 features)
- Only baseline data was used for training

MRI features	Genetic features	DTC features / #missing data
Amygdala - Left	ΑΡΟΕ-ε2	AB40 (CSF) / 41
Amygdala - Right	ΑΡΟΕ-ε3	AB42 (CSF) / 40
Entorhinal - Left	ΑΡΟΕ-ε4	AB (CSF) / 176
Entorhinal - Right	rs524410	ptau (CSF) / 176
Fusiform - Left	rs746947	ptau/AB (CSF) / 176
Fusiform - Right	rs1010616	Tau (CSF) / 176
Hippocampus - Left	rs1864036	tau/AB (CSF) / 176
Hippocampus - Right	rs2085925	Age (DEM) / 0
Inferior-parietal - Left	rs2405940	Sex (DEM) / 0
Inferior-parietal - Right	rs2883782	Education (DEM) / 0
Inferior-temporal - Left	rs4953672	Marital status (DEM) / 0
Inferior-temporal - Right	rs5918417	ADAS11 (TST) / 0
Inferior-lateral-ventricle - Left	rs5918419	ADAS13 (TST) / 1
Inferior-lateral-ventricle - Right	rs6116375	CDRSB (TST) / 0
Middle-temporal - Left	rs6773506	FAQ (TST) / 2
Middle-temporal - Right	rs7627954	LDELTOTAL (TST) / 0
Parahippocampal - Left	rs10465385	MMSE (TST) / 0
Parahippocampal - Right	rs10510985	RAVLT-forgetting (TST) / 1
Precuneus - Left	rs10924809	RAVLT-immediate (TST) / 1
Precuneus - Right	rs12522102	RAVLT-learning (TST) / 1
Supramarginal - Left	rs17197559	RAVLT-%forgetting (TST) / 2

### Method - Deep Survival Model

#### Cox regression model

• Hazard function:  $h(t|x) = h_0(t)exp[g(x)]$ 

#### **Deep Survival Model**

• a non-linear version of the Cox model where g(x) parametrized by a neural network (Multi-Layer-Perceptron)

#### Loss function

- $loss = \sum_i D_i \log(\sum_{j \in R_i} \exp[g(x_j) g(x_i)])$ 
  - $D_i$ : event indicator for subject *i* (1=progressive, 0=non-progressive)
  - *R<sub>i</sub>*: set of all individuals at risk



#### Experiments

#### **6** Feature sets combination

- 1. Genetic data (GEN; 21 features)
- 2. MRI data (MRI; 21 features)
- 3. Demographic + Cognitive Test + CSF (DTC; 21 features)

4. MRI and genetic data (GEN+MRI; 42 features)

- 5. Genetic and DTC data (GEN+DTC; 42 features)
- 6. MRI and DTC data (MRI+DTC;42 features)
- 7. All features (GEN+MRI+ DTC; 63 features)

Integrated Brier Score (IBS)

• The average squared **distances** between the observed  $(y_i)$  and predicted survival probability  $(\hat{p}_i)$ 

• 
$$BS = \frac{1}{N} \sum_{i} (y_i - \widehat{p}_i)^2$$

• 0 < IBS < 1 (the smaller the better)

## **Evaluation Metrics 1 Results**

**IBS** (the smaller the better)

Same conclusion:

- Combining MRI and GEN (MRI+GEN) improves the performance
- DTC works best amongst single modalities
- MRI + GTC improved GTC (not statistical significant)



# **Evaluation Metrics 2**

#### Time-dependent Concordance Index (Ctd-index)

• Compares the order of predicted survival times with true survival times for a random pair of subjects



• 0 < Ctd-index < 1 (the bigger the better)

#### **Evaluation Metrics 1 Results**



GEN

GTC

0.831

GTC

0.798

MRI+GEN+

GTC

Combining **MRI** and **GEN** (MRI+GEN) improves the performance

C<sup>td</sup>-index (the bigger the better)

- **DTC** works best amongst single modalities
- MRI + GTC improved GTC (not statistical significant)

#### Predicted vs. true time-to-conversion difference



### **Predicted vs. true time-to-conversion difference**

- **Predicted time:** the time a subject's survival probability reaches 50%
  - If this doesn't happen: Predicted time = 20 years after initial visit
- More than half of the subjects (80/150 or 53.4%) had a time difference of less than 1.5 years
- The predicted event time was earlier than the actual event time for 37 subjects (24.7%)



Histogram of the differences between the predicted and true event times for **progressive** subjects (150 subjects) using the **GEN+MRI+DTC** feature set

# Feature type comparison

- Dementia onset time prediction
- DTC
  - Demographic
  - Cognitive test
  - Cerebral Spinal Fluid Biomarker



#### Feature Importance Analysis

- Explain and compare the contributions of each feature toward the time-to-conversion prediction
- Determine feature contributions through the permutation importance analysis
- Random shuffling of each feature

#### Feature importance: ALL

- **27/36 features** had a positive effect on performance
  - 6 GEN
  - 9 MRI
  - 12 DTC
- 8 of the top 10 features were from DTC including 7 TST features and 1 DEM
- The most important feature was CDRSB (Clinical Dementia Rating Scale)



#### Feature importance: GEN



- **14/21 features** had a positive effect on performance
- The most important feature was APOE-ε4
- Top 10 most important features were from chromosomes 2, 3, 19, and X

#### Feature importance: MRI



- **15/21 features** had a positive effect on performance
- The most important feature was L-Hippocampus
- Other important features include: L-Amygdala, R-Hippocampus, and R-inferiorparietal

#### Feature importance: DTC



- **19/21 features** had a positive effect on performance
- 8 of the top 10 features were from cognitive tests (TST) and the other 2 were demographic (DEM) features
- The most important feature was Delayed recall variable from the Logical memory test (LDEL-Total)

- Modality comparison for Alzheimer's disease time-to-conversion prediction estimation for subjects at different stages of the disease
  - Genomic factor is better at the prodromal stage (pNC)
  - Neuroimage + CSF is better at early disease stage (pMCI)
- Novel AD-related genomic factors are discovered Explainable AI to explore feature importance

# Acknowledgement



Prof. Suzanne Craft



Prof. Metin Gurcan



Prof. Mirza Faisal Beg



Prof. Lei Wang







Prof. James E. Galvin



Dr. Samuel Lockhart



Dr. Da Ma





Dr. Karteek Popuri



Ms. Ghazal Mirab



Dr. Cedric Beaulac



NORTHWESTERN UNIVERSITY



Dr. Hyunwoo Lee









# Thank you!

#### Q&A